CRISPR technology for immuno-oncology applications

Jianbin Wang; Vitaly Balan; Francesco Marincola

doi:10.1016/bs.mie.2019.05.018

CRISPR technology for immuno-oncology applications

Methods Enzymol. 2020:635:251-266. doi: 10.1016/bs.mie.2019.05.018. Epub 2019 Jun 8.

Authors

Jianbin Wang¹, Vitaly Balan², Francesco Marincola²

Affiliations

¹ Refuge Biotechnologies Inc., Menlo Park, CA, United States. Electronic address: james.wang@refugebiotech.com.
² Refuge Biotechnologies Inc., Menlo Park, CA, United States.

PMID: 32122549
DOI: 10.1016/bs.mie.2019.05.018

Abstract

Emergency of the CRISPR technology, a new genome editing tool, revolutionized the biomedical research field in the past 6 years. At the same time, recent advances in cancer immunotherapy reinvigorated our hope to cure most if not all cancer patients with further development of various treatment options. A combination of the CRISPR technology with immuno-oncology research will undoubtedly accelerate the development of new cancer therapies. This review will focus on the CRISPR system and its applications in immune-oncology including identification of immune-oncology gene targets, generation of cancer animal models, and enabling better cell design and manufacture for adoptive cellular therapies.

Keywords: CAR-T; CRISPR; Cancer; Cas9; Immuno-oncology; Immunotherapy; dCas9; sgRNA.

Publication types

Review

MeSH terms

Animals
CRISPR-Cas Systems / genetics
Clustered Regularly Interspaced Short Palindromic Repeats*
Gene Editing
Humans
Neoplasms* / genetics
Neoplasms* / therapy
Technology